TY - JOUR
T1 - Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients
T2 - ROCK-S, a multicentre historical cohort study
AU - ROCK-S study group collaborators
AU - Futakuchi, Akiko
AU - Morimoto, Takeshi
AU - Ikeda, Yoko
AU - Tanihara, Hidenobu
AU - Inoue, Toshihiro
AU - Aihara, Makoto
AU - Arimura, Shogo
AU - Fukuchi, Takeo
AU - Higashide, Tomomi
AU - Honjo, Megumi
AU - Inatani, Masaru
AU - Inoue, Kenji
AU - Ishida, Kyoko
AU - Ishikawa, Makoto
AU - Iwao, Keiichiro
AU - Kakimoto, Hiroshi
AU - Kawase, Kazuhide
AU - Kimura, Akitoshi
AU - Kinoshita, Shigeru
AU - Kiuchi, Yoshiaki
AU - Kokubun, Taiki
AU - Maekawa, Shigeto
AU - Miyata, Kazunori
AU - Mori, Kazuhiko
AU - Nakakura, Shunsuke
AU - Nakamura, Natsuko
AU - Nakamura, Makoto
AU - Nakazawa, Toru
AU - Namba, Kenichi
AU - Nishida, Takashi
AU - Ohguro, Nobuyuki
AU - Ohtani, Shinichiro
AU - Okumichi, Hideaki
AU - Sakamoto, Mari
AU - Sawada, Akira
AU - Shiokawa, Minako
AU - Sotozono, Chie
AU - Suetake, Aki
AU - Sugiyama, Kazuhisa
AU - Takemoto, Yuko
AU - Tokumo, Kana
AU - Tomita, Goji
AU - Tsuzaki, Satsuki
AU - Udagawa, Sachiko
AU - Ueno, Morio
AU - Yokoyama, Yu
AU - Yoshitomi, Takeshi
AU - Yuasa, Yuki
N1 - Funding Information:
The authors are indebted to Ms. Makiko Ohtroii and Ms. Ai Sunagawa for their role in data management. The authors thank all clinicians for their involvement and contributions to the study. This study was supported by Kowa Company, Ltd., and a representative of Kowa participated in the study concept and reviewing of the final manuscript. However, the study design, operation, data collection, statistical analyses, and drafting of the manuscript were solely conducted by the academic authors. Hidenobu Tanihara has received research funding from Kowa, Santen Pharmaceutical and Senju Pharmaceutical, consulting fees from Kowa, and honoraria for lectures from Kowa, Santen Pharmaceutical and Senju Pharmaceutical. Toshihiro Inoue has received research funding from Alcon Japan, Novartis Pharma, Otsuka Pharmaceutical, Pfizer Japan, and Senju Pharmaceutical, and honoraria for lectures from Kowa, Novartis Pharma, Pfizer Japan, Santen Pharmaceutical, and Senju Pharmaceutical. Makoto Aihara has received honoraria from Santen Pharmaceutical, Otsuka Pharmaceutical, Senju Pharmaceutical, and Kowa. Masaru Inatani’s work has been partially funded by Santen Pharmaceutical and Senju Pharmaceutical, as personal financial interests. Kenji Inoue has received honoraria from Senju Pharmaceutical, Otsuka Pharmaceutical, Kowa, Santen Pharmaceutical, Allergan Japan, Novartis Pharma, and Wakamoto Pharmaceutical. Shigeru Kinoshita has received research funding from Kowa. Taiki Kokubun has received research funding from Tomey corporation. Shigeto Maekawa has received research funding from Kowa, Daiichi sankyo company, and Wakamoto Pharmaceutical. Kazunori Miyata has received research funding from Santen Pharmaceutical, GlaxoSmithKline, Alcon, Senju Pharmaceutical, Sucampo Pharmaceutical, Otsuka Pharmaceutical, Becton Dickinson, Novartis, Johnson & Johnson Vision, and HOYA. Kazuhiko Mori has received research funding from Alcon Japan. Makoto Nakamura has received research funding from Kowa, Santen Pharmaceutical, Senju Pharmaceutical, Novartis Pharma, and Otsuka Pharmaceutical, and honoraria for lectures from Santen Pharmaceutical, Senju Pharmaceutical, and Novartis Pharma. Toru Nakazawa has received research funding from Santen Pharmaceutical, Senju Pharmaceutical, Topcon Corporation, Nidek, and Kowa, and honoraria for lectures from Santen Pharmaceutical, Senju Pharmaceutical, Topcon Corporation, and Kowa, and consultation fee from Santen Pharmaceutical. Yuki Yuasa has received research funding from Kowa, Senju Pharmaceutical and Wakamoto Pharmaceutical. Other authors or collaborators declare no competing financial interests.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - To evaluate the efficacy and safety of ripasudil for treatment of secondary glaucoma, a historical cohort study was conducted at 18 centres in Japan. Adults (age ≥20 years) who needed additional IOP reduction and received topical 0.4% ripasudil between 2014 and 2018 due to three secondary glaucoma subtypes, including uveitic glaucoma (UG), exfoliation glaucoma (EG) or steroid-induced glaucoma (SG) were assessed for mean IOP change from baseline prior to additional treatment with ripasudil. We further evaluated the IOP change in each glaucoma subtype, baseline characteristics of each cohort, course of uveitis-induced inflammation in UG eyes, and proportion of patients in each cohort with adverse events. In 332 eyes from 332 patients eligible for this study, the mean overall IOP reductions from baseline at 1, 3, and 6 months were −5.86 ± 9.04 mmHg (−19.4 ± 25.1%), −6.18 ± 9.03 mmHg (−20.0 ± 27.1%), and −7.00 ± 8.60 mmHg (−23.4 ± 25.6%), respectively. These changes were all statistically significant. Of 332 eyes, 109 eyes had UG, 181 had EG, and 42 eyes had SG. The IOP-lowering effects of ripasudil in UG and SG were significantly greater than those of EG at every time point. This finding could have been related to higher baseline IOP levels in UG and SG. UG patients exhibited significant decreases in mean cell score of the anterior segment after ripasudil treatment. No severe adverse events were reported. These findings suggest that treatment with ripasudil is a safe and effective therapeutic modality for IOP reduction in secondary glaucoma.
AB - To evaluate the efficacy and safety of ripasudil for treatment of secondary glaucoma, a historical cohort study was conducted at 18 centres in Japan. Adults (age ≥20 years) who needed additional IOP reduction and received topical 0.4% ripasudil between 2014 and 2018 due to three secondary glaucoma subtypes, including uveitic glaucoma (UG), exfoliation glaucoma (EG) or steroid-induced glaucoma (SG) were assessed for mean IOP change from baseline prior to additional treatment with ripasudil. We further evaluated the IOP change in each glaucoma subtype, baseline characteristics of each cohort, course of uveitis-induced inflammation in UG eyes, and proportion of patients in each cohort with adverse events. In 332 eyes from 332 patients eligible for this study, the mean overall IOP reductions from baseline at 1, 3, and 6 months were −5.86 ± 9.04 mmHg (−19.4 ± 25.1%), −6.18 ± 9.03 mmHg (−20.0 ± 27.1%), and −7.00 ± 8.60 mmHg (−23.4 ± 25.6%), respectively. These changes were all statistically significant. Of 332 eyes, 109 eyes had UG, 181 had EG, and 42 eyes had SG. The IOP-lowering effects of ripasudil in UG and SG were significantly greater than those of EG at every time point. This finding could have been related to higher baseline IOP levels in UG and SG. UG patients exhibited significant decreases in mean cell score of the anterior segment after ripasudil treatment. No severe adverse events were reported. These findings suggest that treatment with ripasudil is a safe and effective therapeutic modality for IOP reduction in secondary glaucoma.
UR - http://www.scopus.com/inward/record.url?scp=85087076574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087076574&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-66928-4
DO - 10.1038/s41598-020-66928-4
M3 - Article
C2 - 32587304
AN - SCOPUS:85087076574
SN - 2045-2322
VL - 10
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 10308
ER -